Five Countries Reviewed Youth Gender Medicine and Got the Same Answer

Commentary.

Sweden isn't a red state. Finland doesn't have a Republican legislature. Norway's health service isn't run by anybody's church. And yet, one after another, the national health authorities of those countries looked at the evidence behind puberty blockers and cross-sex hormones for minors, and pumped the brakes.

That's the part of this story that got lost in the shouting. The retreat from the affirmation-only model of pediatric gender medicine didn't start in Tennessee. It started in Stockholm and Helsinki, inside socialized health systems, driven by clinicians and civil servants who had no political reason to go looking for trouble.

If you want to argue about this at a family dinner, you should know what the documents actually say. So let's go through them.

Finland moved first, in 2020

Finland's Council for Choices in Health Care, known as COHERE, issued updated recommendations in June 2020. The council concluded that the research base for hormonal interventions in minors was insufficient, and directed that psychosocial support and psychiatric care come first rather than last. Medical intervention for adolescents was pushed to a narrow, centralized, case-by-case track.

Notice the sequencing. Finland didn't say these kids are faking. It said the first move should be treating the anxiety, the depression, the autism, the family stress and everything else in the chart before anybody reaches for a prescription pad.

Sweden followed, and it cost a famous hospital something

Sweden's health technology agency, SBU, had already reviewed the literature and found the certainty of evidence very low. In May 2021, Karolinska University Hospital, a name that carries weight in world medicine, announced it would stop prescribing puberty blockers and cross-sex hormones to patients under 16 outside of approved clinical trials.

Then in February 2022, Sweden's National Board of Health and Welfare, the Socialstyrelsen, updated national guidance. Hormonal treatment for minors was restricted to exceptional cases and research settings. The board's reasoning was blunt for a government document: the risks currently outweigh the possible benefits, because we don't know what the benefits are.

Sit with that for a second. A national health authority said, in effect, we've been doing this for years and we can't demonstrate it works.

Norway called it what it was

In March 2023, Ukom, the Norwegian Healthcare Investigation Board, published a report concluding that the knowledge base for gender-affirming treatment of children and young people was insufficient, and recommended that the national guidelines be revised. Ukom's framing was that these interventions should be understood as experimental.

Not banned. Not condemned. Experimental. Which is a specific word with specific obligations attached to it, including honest consent and a research protocol.

Denmark's central clinic narrowed its referral criteria over the same stretch. The pattern across Scandinavia isn't a coincidence, and it isn't an American culture-war import. Those countries got there first.

The Cass Review is the big one

In England, NHS England commissioned Dr. Hilary Cass, a former president of the Royal College of Paediatrics and Child Health, to conduct an independent review of gender identity services for children. Her interim report landed in 2022. The final report, nearly 400 pages, published in April 2024.

Cass commissioned the University of York to run systematic reviews of the underlying literature. The York team assessed the published studies on puberty blockers and on masculinizing and feminizing hormones and found that only a tiny fraction of them were high quality. Most were small, uncontrolled, short-term, and lost track of a significant share of participants before anybody could say what happened to them.

Cass's summary line has been quoted to death and it's still the right quote: this is an area of remarkably weak evidence.

The Tavistock's Gender Identity Development Service, England's single national clinic for these referrals, closed its doors in spring 2024. NHS England stopped routine prescribing of puberty blockers outside research. In May 2024 the UK government restricted private prescriptions too, and in December 2024 that restriction was made indefinite, with a clinical trial planned to actually generate the data nobody had.

What Cass didn't say

Be accurate about this, because overstating it's how you lose the argument.

Cass didn't say gender dysphoria in kids is fake. She didn't say every young person who transitioned regrets it. She didn't say clinicians were villains. She said the opposite of several things people put in her mouth.

What she said was that these young people had been failed by a system that didn't study what it was doing, that ran on a single-track model, that often skipped past co-occurring mental health conditions, and that couldn't tell parents what the long-term outcomes were because nobody had collected them. She criticized clinics that refused to hand over their patient data for the follow-up study. She was hard on the adults, not the kids.

She also recommended a full service model with proper mental health support, not an empty waiting room. A lot of people cheering the report have no interest in the second half of it. The second half matters.

The American review, and the American court

On May 1, 2025, the U.S. Department of Health and Human Services published its own evidence review of pediatric gender dysphoria treatment. It reached conclusions broadly in line with the European reviews on the strength of the evidence. It was also released without named authors, which drew fair criticism, and it came out of an administration that had already signaled its policy direction in a January 2025 executive order. Read it, but read it knowing that.

Separately, on June 18, 2025, the Supreme Court decided United States v. Skrmetti, upholding Tennessee's law restricting these interventions for minors by a 6-3 vote. Worth understanding precisely: the Court ruled on equal protection, not on medicine. It held that the legislature was allowed to make this call. It didn't certify that the evidence is bad. Courts don't do that.

And the American Academy of Pediatrics hasn't moved. Its board reaffirmed its existing policy in August 2023 while authorizing a systematic review of its own. So the disagreement is live, and anybody telling you it's settled in either direction is selling something.

How to read this stuff yourself

The reports are public. The Cass Review site hosts the final report and the York systematic reviews. SBU, Socialstyrelsen, Ukom and COHERE all publish in English. HHS posted its review online.

Three things to look for when you open any of them:

• Does the study have a control group? An enormous share of this literature is pre-post: measure kids, treat kids, measure kids again. With no comparison group, you can't separate the treatment from time, therapy, attention, or growing up.
• How many people dropped out? If a study starts with 100 and reports on 40, the 60 who left are the story.
• What's the certainty rating? Systematic reviewers grade evidence high, moderate, low or very low. In this field the answer keeps coming back low or very low. That's not a slur. It's a technical finding, and it means the honest sentence is we don't know yet.

Parents get told to defer to consensus. Fine. Go find out what the consensus actually reviewed, and how many kids were in it.